Amivantamab Offers Post-Progression Benefit in EGFRm NSCLC Amivantamab Offers Post-Progression Benefit in EGFRm NSCLC
Even if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a survival benefit over chemotherapy alone, follow-up analyses of PAPILLON and MARIPOSA-2 showed.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Hematology | Lung Cancer | Non-Small Cell Lung Cancer